RECIST Response Evaluation Criteria

Related by string. * : Solid Tumors RECIST . RECIST criteria . modified RECIST criteria / re sponse . Responses . RESPONSE : Computer Emergency Response . Emergency Response Team . Community Emergency Response / Evaluations . EVALUATION : undergo psychiatric evaluation . undergoing psychiatric evaluation / CRITERIA . criterias : Common Criteria certification . Downgrade Criteria June * *

Related by context. Frequent words. (Click for all words.) 80 RECIST criteria 80 Solid Tumors 79 RECIST 69 evaluable patients 67 evaluable 67 cytogenetic response 67 plus dexamethasone 66 complete cytogenetic 66 immunohistochemical 66 Secondary endpoints 66 neoadjuvant 66 Thrombolysis 66 ACR# response 66 neoadjuvant therapy 65 patients evaluable 65 neoadjuvant chemotherapy 65 mucosal healing 65 mg kg dose 64 chemoradiotherapy 64 Secondary endpoints include 64 histologically 63 mycophenolate mofetil 63 peripheral blood mononuclear 63 Secondary endpoints included 63 breast carcinoma 63 chlorambucil 63 HER2 positive metastatic breast 63 Pharmacokinetic 63 Amrubicin 63 histologic 63 Chronic Lymphocytic Leukemia 63 FDG PET 62 DAS# [002] 62 plus prednisone 62 estimated glomerular filtration 62 distant metastasis 62 pharmacodynamic effects 62 HSCT 62 Postoperative 62 SABCS 62 tumor lysis syndrome 62 PRECiSE 62 univariate 62 metastatic renal cell carcinoma 61 DOXIL 61 sustained virologic response 61 fine needle aspiration 61 annualized relapse 61 μg kg 61 mg BID 61 nab paclitaxel 61 decitabine 61 pertuzumab 61 KRAS mutations 61 Tolerability 60 Gemcitabine 60 Carfilzomib 60 HERmark 60 Azedra 60 DAVANAT 60 histopathological 60 peg IFN 60 Trastuzumab 60 Chronic Hepatitis C 60 FOLFOX 60 virologic response 60 median PFS 60 liver transplant recipients 60 ACR# [002] 60 Acute Myocardial Infarction 60 chemoradiation 60 Radiation Therapy Oncology 60 Prognostic 60 multivariate analyzes 60 axitinib 60 plus methotrexate 60 APOPTONE 60 composite endpoint 60 EORTC 60 complete remissions 60 Taxotere ® 60 Metastatic Melanoma 60 peginterferon alfa 2a 59 RTOG 59 non squamous 59 Bevacizumab 59 FOLFIRI 59 malignant pleural mesothelioma 59 intravesical 59 Disease Activity 59 malignant lesions 59 Fludara 59 IPSS 59 xenograft models 59 relapsed refractory multiple myeloma 59 glomerular filtration rate 59 achieved statistical significance 59 NLX P# 59 Erlotinib 59 unresectable 59 Meta Analysis

Back to home page